We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+7.84%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$245M
AUM Growth
-$7.55M
Cap. Flow
+$6.28M
Cap. Flow %
2.56%
Top 10 Hldgs %
55.89%
Holding
90
New
18
Increased
14
Reduced
12
Closed
22

Top Buys

Rank Stock Value
1
SKYE icon
Skye Bioscience
SKYE
+$16M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$10.5M
3
ARGX icon
argenx
ARGX
+$8.8M
4
CTNM
Contineum Therapeutics
CTNM
+$6.91M
5
RZLT icon
Rezolute
RZLT
+$5.84M

Top Sells

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$7.66M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$6.85M
3
AXSM icon
Axsome Therapeutics
AXSM
+$6.52M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$5.22M
5
NGNE icon
Neurogene
NGNE
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 96.66%
2 Consumer Discretionary 1.68%
3 Technology 0.03%
4 Financials 0.01%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOB
76
Mobilicom Ltd
MOB
$71.9M
– –
-135,292
Closed -$161K
NGNE icon
77
Neurogene
NGNE
$711M
– –
-100,000
Closed -$5.09M
OLMA icon
78
Olema Pharmaceuticals
OLMA
$1.02B
– –
-605,000
Closed -$6.85M
PRAX icon
79
Praxis Precision Medicines
PRAX
$10.4B
– –
-78,100
Closed -$4.77M
RYTM icon
80
Rhythm Pharmaceuticals
RYTM
$7.55B
– –
-57,271
Closed -$2.48M
TRML
81
DELISTED
Tourmaline Bio
TRML
– –
-65,442
Closed -$1.5M
VKTX icon
82
PUT
Viking Therapeutics
VKTX
$3.88B
– –
-175,300
Closed -$14.4M
BRSHW
83
DELISTED
Bruush Oral Care Inc. Warrant
BRSHW
– –
-14,423
Closed -$110
ALPN
84
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-77,848
Closed -$3.09M
MRNS
85
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-176,840
Closed -$1.6M
MBTCR
86
DELISTED
Nocturne Acquisition Corporation Right
MBTCR
– –
-500,000
Closed -$82K
DENT
87
CALL
DELISTED
AdvisorShares Dent Tactical ETF
DENT
– –
-1,125,000
Closed -$11.3M
LBPH
88
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-170,000
Closed -$3.67M
OSAAW
89
DELISTED
ProSomnus, Inc. Warrant
OSAAW
– –
-150,000
Closed -$3K
RACYW
90
DELISTED
Relativity Acquisition Corp. Warrant
RACYW
– –
-100,000
Closed –
1 2 3
4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Altium Capital Management held 90 positions worth $245M, down 3% from $253M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Altium Capital Management's Q2 2024 filing shows 18 new, 14 increased, 12 reduced and 22 closed positions. Its largest new stake was Skye Bioscience: 1,350,093 shares worth $10.8M. The largest sale was Biohaven, an estimated $7.66M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 86% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Altium Capital Management's largest Q2 2024 buy was Skye Bioscience: 1,350,093 shares worth $10.8M.
  • Altium Capital Management added most to Intra-Cellular Therapies Inc. in Q2 2024, an estimated $5.55M increase.
  • Altium Capital Management's biggest Q2 2024 reduction was Axsome Therapeutics, cutting an estimated $6.52M.
  • Altium Capital Management fully exited Biohaven in Q2 2024, selling an estimated $7.66M.
  • Altium Capital Management's ten largest holdings make up 56% of its $245M portfolio in Q2 2024.
  • Altium Capital Management opened 18 new positions and closed 22 in Q2 2024.
  • Altium Capital Management's portfolio value fell 3% quarter-over-quarter to $245M.

Based on Altium Capital Management's 13F filing for Q2 2024, filed 15 Aug 2024.